In a cohort of 2880 KRAS mutant NSCLC patients analyzed by Yang et al., PD-L1 expression levels were found to range from 12.82% (Q61 mutation) to 35.21% (G13 mutation) [90]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.